Show simple item record

dc.contributor.authorGoyal, Amit
dc.contributor.authorPuri, Shama
dc.contributor.authorCarmichael, Amtul
dc.contributor.authorErdelyi, Gabriella
dc.contributor.authorYork, Joanne
dc.date.accessioned2020-11-27T11:48:46Z
dc.date.available2020-11-27T11:48:46Z
dc.date.issued2020-10
dc.identifier.citationBreast Cancer Res Treat.2020 Oct 6.doi: 10.1007/s10549-020-05961-3.Online ahead of print.en
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/2341
dc.description.abstractBackground: The primary aim of this prospective, multicentre feasibility study was to determine whether the biopsied axillary node can be marked using black carbon dye and successfully identified at the time of surgery. Methods: We included breast cancer patients undergoing needle biopsy of the axillary node. The biopsied node was tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or at a separate visit with black carbon dye (Spot® or Black Eye™). Participants underwent primary surgery or neoadjuvant chemotherapy (NACT) and axillary surgery (SNB or ALND) as per routine care. Results: 110 patients were included. Median age of the women was 59 (range 31-88) years. 48 (44%) underwent SNB and 62 (56%) ALND. Median volume of dye injected was 2.0 ml (range 0.2-4.2). Tattooed node was identified intra-operatively in 90 (82%) patients. The identification rate was higher (76 of 88, 86%) in the primary surgery group compared with NACT (14 of 22, 64%) (p = 0.03). Of those undergoing NACT, the identification rate was better in the patients undergoing SNB (3 of 4, 75%) compared with ALND (11 of 18, 61%) (p > 0.99). The tattooed node was the sentinel node in 78% (28 of 36) patients in the primary surgery group and 100% (3 of 3) in the NACT group. There was no learning curve for surgeons or radiologists. The identification rate did not vary with timing between dye injection and surgery (p = 0.56), body mass index (p = 0.62) or volume of dye injected (p = 0.25). Conclusion: It is feasible to mark the axillary node with carbon dye and identify it intra-operatively. ClinicalTrials.gov: NCT03640819.en
dc.language.isoenen
dc.subjectAxillary Stagingen
dc.subjectBreast Canceren
dc.subjectCarbon Dyeen
dc.subjectNeoadjuvant Chemotherapyen
dc.subjectSentinel Node Biopsyen
dc.subjectTargeted Axillary Dissectionen
dc.subjectTattooingen
dc.titleA multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patientsen
dc.typeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record